Venetoclax plus bomedemstat for relapsed or hard-to-treat AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests venetoclax together with bomedemstat in adults whose acute myeloid leukemia (AML) has come back or did not respond to standard treatment. The goal is to see whether this combination can control the leukemia safely and help shrink it enough to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that has relapsed (returned) or is refractory (did not respond) after at least one standard treatment
- You are age 18 or older
- Your general health is fairly good (ECOG 0, 1, or 2)
- Your blood counts and organ tests are within required limits (kidney, liver, bilirubin, blood counts)
- You can have frequent blood tests and a bone marrow exam when the study asks
- You can do at least 3 months of treatment, and you agree in writing to study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.